Last reviewed · How we verify

NCT04462367: NCOVIP

Northeast COVID-19 and Pregnancy Study Group

Status unknown Last updated 6 March 2024
What this trial tests

trial in COVID19 in 180 participants. Status unknown.

Timeline
1 July 2020
Primary endpoint
30 June 2023
20 December 2024

Quick facts

Lead sponsorInstituto Materno Infantil Prof. Fernando Figueira
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment180
Start date1 July 2020
Primary completion30 June 2023
Estimated completion20 December 2024
Sites1 location across Brazil

Conditions studied

Sponsor

Instituto Materno Infantil Prof. Fernando Figueira

Who can join

Eligibility, female only, with COVID19 or Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective and retrospective cohort study. The objective will to determine the frequency of COVID-19 in pregnant and postpartum women hospitalized with flu syndrome, to evaluate clinical and laboratory predictors of COVID-19 progression and to determine the factors associated with adverse maternal and perinatal outcomes in healthcare centers in two states of Northeast Brazil.The study will be conducted including pregnant and postpartum women with clinical or laboratorial diagnosis of COVID-19, admitted in six healthcare centers in the Northeast of Brazil. All pregnant and postpartum women with clinical and/or diagnosis of COVID-19, attended in prenatal care, in emergency (maternity triage), high-risk pregnancy ward, obstetric intensive care unit and rooming-in ward will be included. The data will be collected in specific forms. The exams will be carried out by trained professionals within each institution.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity.
    Spini A, Giudice V, Brancaleone V, Morgese MG, et al · · 2021 · cited 21× · PMID 34454035 · DOI 10.1016/j.phrs.2021.105848
  2. Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study.
    Ramírez-Salinas GL, Martínez-Archundia M, Correa-Basurto J, García-Machorro J. · · 2020 · cited 16× · PMID 33260370 · DOI 10.3390/molecules25235615
  3. Clinical and epidemiological profile of pregnant and postpartum women affected by COVID-19 who required respiratory support.
    Cunha CMP, Amorim MMR, Guendler JA, Souza ASR, et al · · 2025 · PMID 40406476 · DOI 10.61622/rbgo/2025rbgo14
  4. Association between maternal and perinatal outcomes and histological changes in the placenta of patients with Covid-19: A cohort study.
    Rocha de Souza L, Ramos Amorim MM, Souza AS, Carvalho Pinto de Melo B, et al · · 2024 · PMID 38788031 · DOI 10.1097/md.0000000000038171
  5. Factors associated with severe acute respiratory syndrome in pregnant/postpartum women with COVID-19 receiving care at referral centers in northeastern Brazil: Secondary analysis of a cohort study.
    Cunha CMP, Amorim MM, de Azevedo Guendler J, Katz L. · · 2023 · PMID 37441093 · DOI 10.1016/j.heliyon.2023.e17131
  6. Factors Associated with Severe Acute Respiratory Syndrome in Pregnant/Postpartum Women with COVID-19 Receiving Care at Referral Centers in Northeastern Brazil: A Cohort Study
    Cunha CMPC, Amorim M, Guendler J, Katz L, et al · · 2022 · DOI 10.2139/ssrn.4261843

Verify or expand the search:

Other recruiting trials for COVID19

Currently open trials in the same condition.

Other Instituto Materno Infantil Prof. Fernando Figueira trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04462367.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing